Entities / Company
Johnson & Johnson.
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- Reports this week
- 15
- Active events
- 17
- Connections
- 591
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
AppLovin fears being in Alphabet's crosshairs, while Compass Pathways avoids Johnson & Johnson due to size.Some support1 report
-
Dividend yields for companies like P&G and J&J are benchmarked against Fed targets, serving investors needing financial advice.Some support3 reports
-
Johnson & Johnson reports mixed sales performance for several key drugs, with Imbruvica and Remicade declining while Darzalex and Tremfya show strong sales.Some support1 report
-
Ben-Zvi worked on campaigns for Johnson & Johnson while overseeing the iProspect business at Dentsu.Some support1 report
-
Johnson & Johnson filed recent stock holdings with the SEC on October 15, 2026.Some support1 report
-
Johnson & Johnson successfully spun off Kenvue to focus on core business, while FED policy signals affect market perception of JNJ.Well supported5 reports4 developments inside
-
Johnson & Johnson's MedTech segment reported sales below expectations and is facing an investigation into federal securities law violations.Some support2 reports
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported4 reports2 developments inside
-
Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.Some support1 report
-
Johnson & Johnson MedTech is facing multiple headwinds from China procurement changes, Middle East disruptions, and AbioMed weakness.Some support1 report
-
Amundi increased its stake in Johnson & Johnson, while Bank of America, Morgan Stanley, and TD Cowen issued rating and price target updates on the company.Some support1 report
-
Conflict in the Middle East impacted sales for Johnson & Johnson.Some support1 report
-
Bank stocks fell on mixed Q3 results, while Johnson & Johnson reported better-than-expected pharma results.Some support2 reports
-
Johnson & Johnson presented clinical data at the American College of Gastroenterology meeting.Some support1 report
-
The FDA approved a new device manufactured by Cordis, a company with a complex history of corporate acquisitions.Some support1 report
-
Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.Some support1 report
-
Johnson & Johnson and TreasuryDirect are competing for investor capital streams.Some support1 report
Earlier this month
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
A global study was conducted on menopausal women's health, alongside collaborations to raise eye health awareness and accept AI regulation recommendations.Some support1 report
-
Cramer suggested both Coca-Cola and Johnson & Johnson as stocks to buy due to stability in a weak economy.Some support1 report
-
Johnson & Johnson highlights its oncology pipeline as a key growth driver.Some support1 report
-
Johnson & Johnson and Bank of America Merrill Lynch participated in the Q3 earnings season on October 7, 2026.Some support1 report
-
On October 7, 2026, Timothy Schmid and Jennifer Taubert sold Johnson & Johnson shares, while Cooper Financial Group boosted its position.Some support2 reports
-
Lloyd Doggett purchased shares of IBM, Johnson & Johnson, Procter & Gamble, and PPG Industries on October 7, 2026.Some support2 reports
-
MarketBeat listed Johnson & Johnson, Medtronic plc, and Eli Lilly and Company as top healthcare stocks on October 7, 2026.Some support2 reports
-
Analyst targets are being lowered amid new entrants challenging market dominance for medical technology companies.Some support1 report1 development inside
-
Jim Cramer advised against Intuitive Surgical stock, citing competition from Johnson & Johnson.Some support2 reports
-
A fund trimmed its position in Johnson & Johnson (JNJ) stock and disclosed the transaction via financial filings with the SEC.Some support3 reports
-
Investigative reporting exposed a pattern of lies involving Larry Foster and Johnson & Johnson.Some support1 report
-
Survey results were presented in Anaheim, CA, by the Director of global medical education at Johnson & Johnson.Some support1 report
-
HSBC provided a buy rating and price target for Johnson & Johnson, while Morgan Stanley raised its price objective to $294.00. The company also filed required 13F reports with the SEC.Some support2 reports
-
P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Well supported10 reports
-
Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Well supported17 reports
-
Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.Well supported14 reports1 development inside
-
Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.Some support1 report
-
The CBO reported an $8.8 billion handout in OBBB, which weakened Medicare drug price negotiation. Bryan Steil voted for the bill benefiting Big Pharma, after receiving donations from lobbyists.Some support1 report
-
Johnson & Johnson announced successful Phase 2 trial data for CARVYKTI in the multiple myeloma therapy market.Some support1 report
-
Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.Some support1 report
-
Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.Some support1 report
-
Nanobiotix and Johnson & Johnson are collaborating on nanotherapeutics. Laurent Levy is the CEO of Nanobiotix.Some support1 report
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Some support1 report
-
Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.Well supported7 reports1 development inside
-
J&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.Some support1 report
-
AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.Some support2 reports1 development inside
-
Johnson & Johnson and Compass Pathways are both involved in the advanced psychedelic therapy market, currently submitting applications for COMP360 approval.Some support1 report
-
A study examined the dividend policy performance of P&G and J&J, contrasting them with growth stocks like Nvidia and Micron.Some support3 reports
-
J&J plans heavy US investment and growth, including a new facility in North Carolina, as discussed by CEO Joaquin Duato.Some support2 reports1 development inside
-
Joaquin Duato guides Johnson & Johnson to achieve double-digit growth.Some support1 report
One to three months ago
-
The event covers disparate news items involving Wipro managing AI systems, SAP usage, and Kumar judging innovation awards.Speculative1 report1 development inside
-
MarketBeat listed UnitedHealth Group, Eli Lilly and Company, Moderna, Thermo Fisher Scientific Inc., Johnson & Johnson, and Illumina as stocks to watch.Some support2 reports
-
Johnson & Johnson, BDX, and Universal Health Realty Income Trust were identified as attractive dividend-paying healthcare stocks.Some support1 report1 development inside
-
Johnson & Johnson and Realty Income are noted for competing dividend investment vehicles.Some support1 report
-
An ETF holds shares of Johnson & Johnson, ExxonMobil, and JPMorgan Chase.Some support1 report
-
Johnson & Johnson is reportedly considering a sale of its orthopedics business unit within DePuy Synthes.Some support2 reports
-
Johnson & Johnson developed JNJ-5120/PIPE-307 under a global license.Some support3 reports
-
Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.Some support2 reports
-
Shipping disruptions are causing procedural changes and increased competition among medical device manufacturers Johnson & Johnson and Boston Scientific.Some support2 reports
-
Financial planning compares private income from dividend-paying companies like Procter & Gamble and Johnson & Johnson against government benefits such as Social Security.Some support1 report2 developments inside
-
Both Procter & Gamble and Johnson & Johnson demonstrated financial resilience during market downturns.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Johnson & Johnson
Events traced to Johnson & Johnson, step by step, newest first- Medtronic's surgical robot entry increases competition for Johnson & JohnsonMedtronic's surgical robot entry increases competition for Johnson & JohnsonPossible
- Medtech's 4.8% U.S. growth supports Johnson & Johnson's revenueMedtech's 4.8% U.S. growth supports Johnson & Johnson's overall revenue outlookAlready happening
- P&G's growth risks may shift investor focus toward Johnson & JohnsonP&G's growth risks may shift investor focus toward Johnson & JohnsonPossible
- Intuitive Surgical's strong margins may increase competitive pressure on Johnson & JohnsonIntuitive Surgical's growth may increase competitive pressure on Johnson & JohnsonPossible
- How could high I Bond rates affect Johnson & Johnson's investment appeal?High I Bond rates may draw investor capital away from stocksPossible
- Johnson & Johnson may face reputational and financial risk from Abiomed's kickback fineJohnson & Johnson may face reputational and financial risk from Abiomed's kickback finePossible
See all 8 explainers
Explainers that pass through Johnson & Johnson
Johnson & Johnson is a step on the way to someone elseAround Johnson & Johnson this week
News at the entities that move Johnson & Johnson most-
Joaquin Duato StructuralMedtech reported 4.8% growth in the U.S., with Joaquin Duato serving as Chairman and CEO.Moves Johnson & Johnson
-
SEC StructuralThe SEC has mandated that filings regarding ETF holdings must be submitted.Moves Johnson & Johnson
-
Zymeworks StructuralZymeworks and Cytokinetics are companies operating in the medical/biomedical sector.Moves Johnson & Johnson
-
FDA StructuralAbbott Laboratories faces an FDA recall classification of its sensors, while Ken Fisher and Donald Trump engage in stock transactions.Moves Johnson & Johnson
-
Donald Trump OperationalTrump directed agencies to rename Lake Ontario and Denali, while also calling for a state name change in New Mexico that was rejected by Gregg Hull.Moves Johnson & Johnson
-
Daiwa Securities Group OperationalDaiwa Securities Group filed a 13F report with the SEC and provided a research note with a price objective for SpaceX.Moves Johnson & Johnson
Connections
The 40 strongest of 591, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Berkshire Hathaway Structural
Berkshire Hathaway historically owned Johnson & Johnson.
-
Medtech Structural
Medtech functions as a core business segment and subsidiary within Johnson & Johnson's corporate structure.
-
Joaquin Duato Structural
Joaquin Duato holds the executive leadership roles of CEO and Chairman at Johnson & Johnson.
-
SEC Structural
Johnson & Johnson is subject to mandatory financial and disclosure regulations enforced by the SEC.
-
Legend Biotech Structural
Legend Biotech and Johnson & Johnson maintain a deep structural partnership, co-developing and supplying the CARVYKTI treatment, cemented by J&J's investment in Legend's portfolio.
-
Kenvue Structural
Kenvue was formed as a spin-off of Johnson & Johnson's consumer health business unit.
-
Howard Reid Structural
Howard Reid serves as the VP of corporate brand at Johnson & Johnson.
-
Zymeworks Structural
Johnson & Johnson utilizes Zymeworks' proprietary technology platform for the development and production of clinical-stage antibodies.
Show all 40 connections
-
Eli Lilly and Company Operational
The two pharmaceutical giants are engaged in direct, high-stakes market competition across various therapeutic and growth segments.
-
CORDIS Structural
Johnson & Johnson acquired Cordis in 1996, establishing Cordis as a subsidiary.
-
Intuitive Surgical Operational
Intuitive Surgical and Johnson & Johnson are active market rivals competing for dominance in the surgical robotics and minimally invasive medical device sectors.
-
FDA Structural
The FDA functions as the mandatory regulatory gatekeeper, evaluating and granting market access approvals for Johnson & Johnson's medical and pharmaceutical products.
-
Jim Cramer Operational
Jim Cramer provides investment commentary and recommendations regarding Johnson & Johnson's stock performance and business health.
-
Genmab Structural
Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab under an exclusive license agreement.
-
AbioMed Structural
Johnson & Johnson owns and operates AbioMed as a subsidiary, with AbioMed's performance impacting J&J's growth.
-
Amgen Operational
Johnson & Johnson and Amgen actively compete in the biopharma sector, particularly in immunology and bispecific antibodies.
-
Pfizer Operational
Pfizer and Johnson & Johnson are major pharmaceutical competitors operating in shared markets, facing common industry pressures and competing for investment capital.
-
Boston Scientific Operational
Both companies are major competitors in the medical device and endoscopy markets.
-
Merck Operational
Johnson & Johnson and Merck are major pharmaceutical companies actively competing for market share in specialized drug sectors like oncology and PAH.
-
Procter & Gamble Operational
Both companies are direct competitors in the consumer staples market, frequently compared based on dividend growth and financial resilience.
-
Donald Trump Operational
Trump's political policies and tariff threats significantly influence J&J's operational strategy and market outlook, while J&J is also referenced in Trump's financial disclosures.
-
Abbott Laboratories Operational
Both companies are major healthcare giants that actively compete for market share through product innovation and strategic moves.
-
Janssen Biotech Structural
Janssen Biotech operates as a licensed entity under Johnson & Johnson.
-
AbbVie Operational
AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology.
-
Vanguard Structural
Vanguard holds shares of Johnson & Johnson as part of its investment portfolio.
-
HAAS Structural
Erik Haas serves as the Vice President of Litigation for Johnson & Johnson.
-
Idorsia Transactional
Idorsia was acquired by Johnson & Johnson, leading to its subsequent spin-off.
-
Daiwa Securities Group Operational
Daiwa Securities Group actively influences Johnson & Johnson's market valuation through analyst reports and price target adjustments.
-
Viswanathan Transactional
Viswanathan previously held a sales and marketing role at Johnson & Johnson.
-
Jacksonville Structural
Johnson & Johnson is expanding its U.S. Vision manufacturing operations in Jacksonville with a $1 billion investment.
-
Amundi Transactional
Amundi increased its investment holdings and stake in Johnson & Johnson shares during 2026.
-
AC Immune Structural
AC Immune collaborates with Johnson & Johnson on drug evaluation, with milestone payments triggered by trial progress.
-
Protagonist Therapeutics (United States) Structural
Protagonist Therapeutics and Johnson & Johnson maintain a strategic partnership involving the joint development and licensing of the drug Icotrokinra.
-
Acuvue Structural
Johnson & Johnson operates and launches products under the Acuvue brand.
-
Morgan Stanley Operational
Morgan Stanley provides financial analysis and price targets for Johnson & Johnson shares, and J&J participates in MS events.
-
Meredith Bishop Structural
Meredith Bishop serves as the Director of global medical education at Johnson & Johnson.
-
John Reed Structural
John Reed serves as an Executive Vice President at Johnson & Johnson and is a member of the Executive Committee.
-
SPDR Structural
SPDR ETF holds Johnson & Johnson as a major investment position, representing a formal ownership stake.
-
company Structural
Johnson & Johnson maintains a structural dependency on the entity 'company' through receiving royalties from a collaboration.
-
Tom Cavanaugh Structural
Forecasted leadership role of Tom Cavanaugh within the Innovative Medicine division of Johnson & Johnson.
History
Events by the month they beganOctober 2026
25 events- AppLovin fears being in Alphabet's crosshairs, while Compass Pathways avoids Johnson & Johnson due to size.
- Johnson & Johnson reports mixed sales performance for several key drugs, with Imbruvica and Remicade declining while Darzalex and Tremfya show strong sales.
- Ben-Zvi worked on campaigns for Johnson & Johnson while overseeing the iProspect business at Dentsu.
- Johnson & Johnson filed recent stock holdings with the SEC on October 15, 2026.
- Johnson & Johnson's MedTech segment reported sales below expectations and is facing an investigation into federal securities law violations.
- Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.
- Johnson & Johnson MedTech is facing multiple headwinds from China procurement changes, Middle East disruptions, and AbioMed weakness.
- Amundi increased its stake in Johnson & Johnson, while Bank of America, Morgan Stanley, and TD Cowen issued rating and price target updates on the company.
- Conflict in the Middle East impacted sales for Johnson & Johnson.
- Bank stocks fell on mixed Q3 results, while Johnson & Johnson reported better-than-expected pharma results.
- Johnson & Johnson presented clinical data at the American College of Gastroenterology meeting.
- The FDA approved a new device manufactured by Cordis, a company with a complex history of corporate acquisitions.
- Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.
- Johnson & Johnson and TreasuryDirect are competing for investor capital streams.
- Major pharmaceutical companies are competing for investment capital.
- A global study was conducted on menopausal women's health, alongside collaborations to raise eye health awareness and accept AI regulation recommendations.
- Cramer suggested both Coca-Cola and Johnson & Johnson as stocks to buy due to stability in a weak economy.
- Johnson & Johnson highlights its oncology pipeline as a key growth driver.
- Johnson & Johnson and Bank of America Merrill Lynch participated in the Q3 earnings season on October 7, 2026.
- On October 7, 2026, Timothy Schmid and Jennifer Taubert sold Johnson & Johnson shares, while Cooper Financial Group boosted its position.
- Lloyd Doggett purchased shares of IBM, Johnson & Johnson, Procter & Gamble, and PPG Industries on October 7, 2026.
- MarketBeat listed Johnson & Johnson, Medtronic plc, and Eli Lilly and Company as top healthcare stocks on October 7, 2026.
- Jim Cramer advised against Intuitive Surgical stock, citing competition from Johnson & Johnson.
- Investigative reporting exposed a pattern of lies involving Larry Foster and Johnson & Johnson.
- Survey results were presented in Anaheim, CA, by the Director of global medical education at Johnson & Johnson.
September 2026
21 events- Dividend yields for companies like P&G and J&J are benchmarked against Fed targets, serving investors needing financial advice.
- HSBC provided a buy rating and price target for Johnson & Johnson, while Morgan Stanley raised its price objective to $294.00. The company also filed required 13F reports with the SEC.
- Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.
- The CBO reported an $8.8 billion handout in OBBB, which weakened Medicare drug price negotiation. Bryan Steil voted for the bill benefiting Big Pharma, after receiving donations from lobbyists.
- Johnson & Johnson announced successful Phase 2 trial data for CARVYKTI in the multiple myeloma therapy market.
- Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.
- Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.
- Nanobiotix and Johnson & Johnson are collaborating on nanotherapeutics. Laurent Levy is the CEO of Nanobiotix.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- J&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.
- Johnson & Johnson and Compass Pathways are both involved in the advanced psychedelic therapy market, currently submitting applications for COMP360 approval.
- A study examined the dividend policy performance of P&G and J&J, contrasting them with growth stocks like Nvidia and Micron.
- Joaquin Duato guides Johnson & Johnson to achieve double-digit growth.
- MarketBeat listed UnitedHealth Group, Eli Lilly and Company, Moderna, Thermo Fisher Scientific Inc., Johnson & Johnson, and Illumina as stocks to watch.
- Johnson & Johnson and Realty Income are noted for competing dividend investment vehicles.
- An ETF holds shares of Johnson & Johnson, ExxonMobil, and JPMorgan Chase.
- Johnson & Johnson is reportedly considering a sale of its orthopedics business unit within DePuy Synthes.
- Johnson & Johnson developed JNJ-5120/PIPE-307 under a global license.
- Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.
- Shipping disruptions are causing procedural changes and increased competition among medical device manufacturers Johnson & Johnson and Boston Scientific.
- Both Procter & Gamble and Johnson & Johnson demonstrated financial resilience during market downturns.
August 2026
2 eventsShow 2 earlier months
July 2026
2 eventsJune 2026
10 events- Johnson & Johnson successfully spun off Kenvue to focus on core business, while FED policy signals affect market perception of JNJ.
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.
- Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.
- J&J plans heavy US investment and growth, including a new facility in North Carolina, as discussed by CEO Joaquin Duato.
- The event covers disparate news items involving Wipro managing AI systems, SAP usage, and Kumar judging innovation awards.
- Johnson & Johnson, BDX, and Universal Health Realty Income Trust were identified as attractive dividend-paying healthcare stocks.